Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down to $8.66

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPHGet Rating) gapped down before the market opened on Tuesday . The stock had previously closed at $8.66, but opened at $8.48. Theravance Biopharma shares last traded at $8.61, with a volume of 1,469 shares.

Several brokerages have recently issued reports on TBPH. SVB Leerink initiated coverage on shares of Theravance Biopharma in a report on Monday, May 23rd. They issued an “outperform” rating and a $12.00 target price on the stock. HC Wainwright raised their price objective on Theravance Biopharma from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 24th. Morgan Stanley lifted their price target on Theravance Biopharma from $10.00 to $11.00 and gave the stock an “underweight” rating in a research report on Wednesday, March 2nd. Finally, StockNews.com assumed coverage on Theravance Biopharma in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Theravance Biopharma has an average rating of “Hold” and an average price target of $11.75.

The business has a 50-day moving average of $9.31 and a 200-day moving average of $9.63.

Theravance Biopharma (NASDAQ:TBPHGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.12). The company had revenue of $13.20 million during the quarter, compared to the consensus estimate of $16.51 million. On average, equities analysts forecast that Theravance Biopharma, Inc. will post 0.06 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. UBS Group AG lifted its position in shares of Theravance Biopharma by 45.0% during the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Theravance Biopharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 62,531 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 1,682 shares during the period. California State Teachers Retirement System increased its stake in shares of Theravance Biopharma by 2.7% during the third quarter. California State Teachers Retirement System now owns 75,440 shares of the biopharmaceutical company’s stock valued at $558,000 after buying an additional 1,983 shares during the period. Swiss National Bank increased its stake in shares of Theravance Biopharma by 1.9% during the fourth quarter. Swiss National Bank now owns 121,342 shares of the biopharmaceutical company’s stock valued at $1,341,000 after buying an additional 2,300 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Theravance Biopharma by 51.6% during the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,818 shares during the period. Institutional investors and hedge funds own 78.14% of the company’s stock.

Theravance Biopharma Company Profile (NASDAQ:TBPH)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Featured Articles

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.